AMH Test and PCOS / PMOS — 2026 Thresholds by Age
Since the ESHRE/Monash 2023 guideline, AMH (Anti-Müllerian Hormone) is officially recognized as a PCOS/PMOS diagnostic criterion — equivalent to ultrasound. Understanding your result and its limitations is essential to avoid misinterpretation and unnecessary anxiety.
What is AMH (Anti-Müllerian Hormone)?
AMH is a glycoprotein produced by granulosa cells of pre-antral and early antral ovarian follicles (2–8 mm diameter). Its production is proportional to the number of active follicles — making it a direct measure of ovarian follicular reserve. Unlike other reproductive hormones (FSH, LH, estradiol), AMH shows little variation throughout the menstrual cycle, which means it can be tested at any point in the cycle — on day 2, day 10, or day 22, results are comparable.
AMH is undetectable before puberty, peaks between ages 20–25, then declines progressively until menopause where it becomes undetectable again. This predictable trajectory makes AMH a reliable longitudinal marker of ovarian aging. In PCOS/PMOS, ovaries contain an abnormally high number of small antral follicles — often two to four times more than in women without the condition. Each of these follicles produces its share of AMH, which is why women with PMOS consistently show AMH levels 2 to 4 times higher than age-matched controls. This is not a sign of superior fertility, but of follicular accumulation and arrested maturation.
The biological mechanism behind this elevation is now well established: in PCOS, elevated androgens and insulin resistance both stimulate early follicular growth while simultaneously blocking the selection of a dominant follicle. The result is a pool of stalled small follicles, each contributing AMH, driving levels abnormally high. Sources: Dewailly et al. 2014, Human Reproduction Update; ESHRE International Guideline 2023; Pigny et al. 2023, Fertility and Sterility.
Why AMH became a PCOS diagnostic criterion in 2023
Historically, PCOS diagnosis relied on the Rotterdam 2003 criteria, which included polycystic ovarian morphology (PCOM) assessed on ultrasound — defined as 20 or more follicles of 2–9 mm per ovary, or ovarian volume of 10 mL or more. This approach worked well in centers with high-quality transvaginal ultrasound equipment and experienced sonographers, but posed real challenges in routine clinical practice across different healthcare systems.
The ESHRE/Monash 2023 International Evidence-Based Guideline on PCOS formally recognized that AMH measurement — performed on a validated laboratory analyzer — can replace ultrasound for PCOM assessment in adult women aged 20 years and older. This change reflects years of validation studies confirming that AMH correlates strongly with follicle count on high-resolution ultrasound (r ≈ 0.70–0.80) and that a defined threshold identifies PCOM with acceptable sensitivity and specificity.
The practical rationale is compelling: transvaginal ultrasound is operator-dependent, machine-dependent, and invasive for many patients. AMH is reproducible, standardizable across visits, inexpensive relative to imaging, and requires no specialist technician. The essential condition for this substitution is that the laboratory must have validated its age-specific thresholds on its specific analytical platform — whether the Elecsys Roche system, Beckman Access, or another validated analyzer. Results from different platforms are not interchangeable. Source: Teede et al. 2023, ESHRE International Evidence-Based Guideline on PCOS; JCEM 2024.
AMH thresholds by age — 2026 reference table
The thresholds below are indicative of current clinical practice. Always use your laboratory's own reference values, as thresholds vary meaningfully by analyzer platform and assay generation. For context, values from older assay generations (pre-2012 Beckman) are not comparable to current Elecsys or Gen II values. Conversion: 1 ng/mL = 7.14 pmol/L.
| Age | Normal AMH (ng/mL) | Suspect PCOS threshold | Strongly suggestive PCOS |
|---|---|---|---|
| 20–25 years | 1.0 – 3.3 ng/mL (7–24 pmol/L) | 3.4 – 5.0 ng/mL | > 5.0 ng/mL (> 36 pmol/L) |
| 26–30 years | 0.9 – 2.9 ng/mL | 3.0 – 4.5 ng/mL | > 4.5 ng/mL |
| 31–35 years | 0.7 – 2.4 ng/mL | 2.5 – 4.0 ng/mL | > 4.0 ng/mL |
| 36–40 years | 0.4 – 1.8 ng/mL | 1.9 – 3.5 ng/mL | > 3.5 ng/mL |
| > 40 years | 0.1 – 1.1 ng/mL | 1.2 – 2.5 ng/mL | > 2.5 ng/mL |
Most cited diagnostic threshold (ESHRE 2023, Elecsys Roche analyzer): ≥ 3.4 ng/mL at age 25. Sources: Dewailly 2014; JCEM 2024; Pigny 2023, Fertility and Sterility.
Interpretation pitfalls — what can distort your result
1. Combined oral contraceptives (the pill) reduce AMH by 20–30%. This is the single most common source of underestimation in clinical practice. Testing while on an estrogen-progestogen pill underestimates your true AMH value. For a reliable PCOS workup, two options: test after at least 3 months stable on the pill (the value will be stable but still underestimated) or wait 2–3 menstrual cycles after stopping the pill. The choice depends on your clinical situation and whether you can tolerate stopping the pill for diagnostic purposes.
2. AMH is NOT a fertility test. This is a critical distinction that is frequently misunderstood. High AMH indicates a large pool of follicles — it says nothing about oocyte quality, embryo development potential, or the ability to conceive. Women with very high AMH (PCOS-range) can still face ovulatory infertility. Conversely, low AMH indicates reduced reserve but absolutely does not predict infertility — many women with low AMH conceive spontaneously.
3. Chemotherapy and pelvic radiotherapy reduce AMH — sometimes irreversibly and dramatically. AMH is used clinically to monitor ovarian reserve before and after gonadotoxic cancer treatment, and to assess whether ovarian function has been preserved or whether fertility preservation was successful.
4. Endometriosis reduces AMH, sometimes substantially — particularly after surgical treatment of endometriomas. This can mask underlying PCOS (both conditions can coexist) or create a misleading impression of normal or reduced reserve when PCOS is present.
5. Inter-laboratory and inter-platform variation is significant. A value of 3.0 ng/mL on Elecsys is not equivalent to 3.0 ng/mL on an older assay. Always compare your result to the same laboratory's validated reference range. Never compare raw numbers from results obtained at different labs. Sources: Pigny 2023, Fertility and Sterility; JCEM 2024 consensus.
6. Age below 20 years — caution. In adolescents, AMH thresholds for PCOS have not been validated with the same rigor as in adults. ESHRE 2023 recommends ultrasound as the preferred PCOM assessment tool in women under 20, given the higher baseline variability of AMH during adolescence.
AMH vs antral follicle count (AFC) — complementary tools
AMH and AFC (antral follicle count on pelvic ultrasound) measure related but physiologically distinct aspects of ovarian reserve. AMH reflects the total follicular pool including pre-antral follicles too small to visualize on standard 2D ultrasound. AFC counts only follicles visible on the day of scanning, typically those 2–9 mm in diameter. Both provide valid and complementary information.
The correlation between AMH and AFC is strong in population studies (r ≈ 0.70) but discordances occur in individual patients. AFC varies more within the menstrual cycle than AMH — follicles counted on day 2 may differ from those seen on day 10. Functional cysts, examiner experience, machine resolution, and patient body habitus all influence AFC. AMH shows less within-cycle variability (typically less than 15%) and is more reproducible across visits when analytical conditions are standardized.
In expert reproductive medicine centers with high-resolution transvaginal ultrasound and trained sonographers, AFC with the updated ESHRE 2023 threshold (≥ 20 follicles per ovary on high-frequency probe) remains the reference standard. In primary care or in settings where such equipment is unavailable, AMH on a validated platform is an excellent and often superior alternative. In women where results conflict, clinicians use both alongside clinical history. Source: ESHRE 2023 International Guideline.
What to do with a high or low AMH result
High AMH (above age-specific threshold): This is the first step of a workup, not a diagnosis. The next steps are completing the full PCOS evaluation: document cycle regularity (menstrual history, diary, LH strips), obtain a hormonal panel (FSH, LH, free and total testosterone, SHBG, DHEA-S, 17-OH-progesterone, prolactin, TSH). If 2 of the 3 Rotterdam criteria are met (irregular cycles, clinical or biochemical hyperandrogenism, polycystic ovarian morphology including elevated AMH) — PCOS diagnosis is confirmed. Assess for insulin resistance via HOMA-IR. Source: Endocrine Society Clinical Practice Guideline 2024.
Very low AMH for age (e.g. < 0.3 ng/mL before age 35): Consider premature ovarian insufficiency (POI), severe bilateral endometriosis, prior ovarian surgery, or autoimmune ovarian damage. An in-depth fertility workup including FSH and estradiol on day 2–3 of the cycle, and karyotype in some cases, is warranted promptly — especially in women under 40 with irregular cycles. Referral to a reproductive endocrinologist is appropriate.
How to request the AMH test and what to expect
AMH can be ordered by your gynecologist, primary care provider, reproductive endocrinologist, or in some US states via direct-to-consumer laboratory services. The blood draw can be done at any point in the menstrual cycle — no specific timing is required. Results are typically available within 2–5 business days. In the US, insurance coverage for AMH varies: it is generally covered when ordered as part of a fertility evaluation or when PCOS is being assessed under a documented diagnostic code. Out-of-pocket cost without insurance typically ranges from $30 to $80 depending on laboratory. Always request results in both ng/mL and pmol/L to facilitate comparison with international literature. Keep a copy of results including the laboratory name, assay platform used, and the date of testing — this context is essential for accurate interpretation at future visits.
AMH and PCOS management — ongoing monitoring
In women with confirmed PCOS, serial AMH measurements can serve as a useful monitoring tool. Several studies have documented modest AMH reduction with lifestyle interventions — particularly significant weight loss (10–15% body weight) in women with obesity-associated PCOS. Metformin has been associated with AMH reduction in some but not all studies, possibly via insulin-sensitizing effects on granulosa cells. However, AMH is not a validated treatment response marker in routine clinical practice as of 2026 — its change does not reliably predict ovulation restoration or fertility improvement at the individual level. It should not replace cycle monitoring (basal body temperature, LH testing) as a primary ovulation tracking tool. Sources: Pigny 2023; Cochrane 2022 (metformin in PCOS); ESHRE 2023.
Frequently asked questions about AMH and PCOS
- Can AMH replace ultrasound for PCOS diagnosis?
- Yes, per ESHRE/Monash 2023 — in adult women aged 20 years and older, on a validated laboratory analyzer. In women under 20 or in centers without a validated assay platform, transvaginal ultrasound remains the preferred method for assessing polycystic ovarian morphology.
- Does the pill affect AMH results?
- Yes — combined oral contraceptives reduce measured AMH by 20–30%. For a reliable result in a PCOS workup, test after at least 3 months stable on the pill, or 2–3 full cycles after stopping. The latter gives a closer estimate of your unaffected baseline.
- My AMH is high — does that mean I have PCOS?
- Not automatically. PCOS requires 2 of 3 Rotterdam criteria. High AMH fulfills the polycystic ovarian morphology criterion, but you still need at least one additional criterion (irregular cycles or hyperandrogenism). High AMH alone, in a woman with regular cycles and no androgen excess, is not sufficient for PCOS diagnosis.
- AMH vs AFC — which is more useful?
- Both are valid and complementary. AMH is more reproducible visit-to-visit and less operator-dependent. AFC with an expert sonographer on a high-resolution probe is the reference standard in specialized centers. When both are available, they provide additional information when they disagree.
- Is AMH testing covered by insurance in the US?
- Coverage varies by insurer and plan. It is generally covered as part of a documented fertility or PCOS evaluation. Out-of-pocket cost is typically $30–80. Ask your physician to order it as part of a fertility panel or under a PCOS evaluation code for better coverage probability.
Learn more
General information only. This content is not a substitute for medical advice. AMH results require interpretation by a qualified healthcare provider in full clinical context. Sources: ESHRE/Monash International Evidence-Based Guideline on PCOS 2023; Dewailly et al. 2014 (Human Reproduction Update); Pigny et al. 2023 (Fertility and Sterility); JCEM 2024. See our scientific sources page.